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A B S T R A C T
Irritable bowel syndrome (IBS) is a common gastrointestinal disorder of unknown aetiology for which there is no
effective treatment. Although IBS does not increase mortality, it reduces the quality of life and is an economic burden
to both the patients themselves and society as a whole. Peptide YY (PYY) is localized in endocrine cells located in the
ileum, colon and rectum. The concentration of PYY and the density of PYY cells are decreased in both the colon and
rectum but unchanged in the ileum of patients with IBS. The low density of PYY cells in the large intestine may be
caused by a decreased number of stem cells and their progeny toward endocrine cells. PYY regulates the intestinal
motility, secretion and absorption as well as visceral sensitivity via modulating serotonin release. An abnormality in
PYY may therefore contribute to the intestinal dysmotility and visceral hypersensitivity seen in IBS patients. Diet
management involving consuming a low-FODMAP diet restores the density of PYY cells in the large intestine and
improves abdominal symptoms in patients with IBS. This review shows that diet management appears to be a
valuable tool for correcting the PYY abnormalities in the large intestine of IBS patients in the clinic.
1. Introduction
Irritable bowel syndrome (IBS) is a common gastrointestinal dis-
order worldwide (El-Salhy, 2012, 2015). Moreover, about one-third of
patients with ulcerative colitis and about a half of patients with Crohn's
disease suffer from IBS while in remission (Ansari et al., 2008; El-Salhy
et al., 2014b; El-Salhy et al., 2014d; Isgar et al., 1983; Keohane et al.,
2010; Minderhoud et al., 2004; Simren et al., 2002). In addition, about
one-third of patients with coeliac disease suffer from IBS symptoms
despite adhering to a gluten-free diet (El-Salhy et al., 2015). The main
symptoms of IBS are recurrent abdominal pain and altered bowel habits
(El-Salhy, 2015). Symptoms vary in both their degree and temporal
pattern between patients: from mild to severe, and from daily symp-
toms to being symptom-free for months (Agreus et al., 1995; Drossman
et al., 1993). IBS is usually diagnosed in patients younger than 50 years
(Agreus et al., 1995; Drossman et al., 1993). The aetiology of IBS is
unknown and the condition lacks an effective treatment.
2. Peptide YY
Since its discovery, peptide YY (PYY) has been found in the
endocrine cells that are present between the epithelial cells lining the
human ileum, colon and rectum (El-Salhy et al., 1983a; Tatemoto,
1982a; Tatemoto and Mutt, 1980). PYY cells have also been found in
the intestine of several vertebrates (El-Salhy, 1984; El-Salhy et al.,
1981; El-Salhy et al., 1982; El-Salhy et al., 1983b).
Like other enteroendocrine cells, PYY cells have specialized sen-
sory microvilli projecting into the intestinal lumen, and they respond
to luminal stimuli such as nutrients by releasing their hormones into
the lamina propria (Furness et al., 1999; Furness et al., 2013). A
protein-rich meal reportedly stimulates the release of PYY (El-Salhy
et al., 2016). PYY cells also possess a basal cytoplasmic process that is
about 70 μm long and is believed to be involved in their paracrine
mode of action (Bohorquez et al., 2011). This process has been shown
to exhibit neuronal axon-like characteristics, and has been named a
neuropod (Bohorquez et al., 2011; Bohorquez et al., 2014; Bohorquez
et al., 2015). Enteroendocrine cells—and most probably including
PYY cells—contain synaptic vesicles and synthetize presynaptic pro-
teins such as synapsin 1, piccolo, bassoon, MUNC13B, RIMS2, la-
trophilin, and transsynaptic neurexin (Bohorquez et al., 2014;
Bohorquez et al., 2015). These cells also synthetize transsynaptic
neuroligins 2 and 3, homer 3, and postsynaptic density 95 (Bohorquez
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et al., 2015). Thus, PYY cells possess the elements necessary for both
afferent and efferent synaptic transmission (Bohorquez et al., 2015).
These findings suggest that PYY released in the lamina propria could
act locally on close-by cells or neurons (in paracrine mode), via the
circulating blood (in endocrine mode), or by afferent and efferent
synaptic transmission (Fig. 1).
The density of PYY cells differs considerably between the rectum,
colon and ileum, being highest in the rectum followed by the ileum and
then the colon. It is known that PYY and oxyntomodulin (en-
teroglucagon) as well as glucagon-like peptide 1 (GLP-1) are produced
from the same endocrine cell (L cells) (Habib et al., 2013; Spangeus
et al., 2000). In this aspect PYY cells are similar to other enteroendo-
crine cells, which are capable of expressing up to seven different hor-
mones (Egerod et al., 2012; Mortensen et al., 2003; Pyarokhil et al.,
2012).
PYY belongs to the neuropeptide Y (NPY) family that comprises
PYY, NPY and pancreatic polypeptide (Adrian et al., 1985; Tatemoto,
1982a, 1982b; Tatemoto and Mutt, 1980; Tatemoto et al., 1985). These
three structurally related peptides consist of 36 amino-acid residues and
act as hormones and/or neurotransmitters/neuromodulators (Vona-
Davis and McFadden, 2007). PYY and the other two members of the
NPY family exert their functions through binding to at least six Y-re-
ceptor subtypes of transmembrane-domain G-protein-coupled receptors
(Vona-Davis and McFadden, 2007).
3. PYY regulatory functions and mode of action
PYY and NPY exert similar biological effects and bind to and ac-
tivate receptors Y1, Y2 and Y5 (Cox et al., 2001; Cox and Tough, 2002;
Hyland and Cox, 2005; Hyland et al., 2003). Receptors Y1 and Y2 are
localized in epithelial cells and submucosal and myenteric plexus
neurons of the small intestine and colon (Cox et al., 2001; Cox and
Tough, 2002; Gregor et al., 1996a; Gregor et al., 1996b; Gue et al.,
1996; Inui et al., 1992; Mao et al., 1996; Sheikh and Williams, 1990;
Walsh et al., 1993; Wharton et al., 1993; Yan et al., 1996). This ex-
plains why PYY and NPY exert similar effects in the gastrointestinal
tract, although PPY is much more potent than NYY (Gomez et al.,
1995).
PYY exert multiple physiological effects in the gastrointestinal tract.
It delays gastric emptying, is a mediator of the ileal brake, inhibits
gastric and pancreatic secretion, and stimulates the absorption of water
and electrolytes (El-Salhy et al., 2014b; El-Salhy et al., 2012; Vona-
Davis and McFadden, 2007). Furthermore, PYY seems to play an im-
portant role in modulating serotonin release from colonic en-
terochromaffin cells via the endogenous NK2/NK3 cascade system
(Kojima et al., 2015). Serotonin is known to modulate visceral sensi-
tivity and increase gastrointestinal motility and intestinal secretion (El-
Salhy et al., 2012b; El-Salhy et al., 2012).
PPY also regulates the appetite and food intake (Konturek et al.,
2004; Nguyen et al., 2011). PYY is released into the circulation in
response to meal ingestion (Adrian et al., 1985), and a reduction in
food consumption following the infusion of PYY3–36 has been re-
ported during test meals. Moreover, the plasma concentration of PYY
is low in obese subjects (Batterham et al., 2003; Batterham et al.,
2002). The arcuate nucleus (ARC) in the median eminence is the
centre for integrating neurological and blood-borne signals (Cone
et al., 2001; Peruzzo et al., 2000; Yu and Kim, 2012). The ARC lacks a
complete blood–brain barrier and the brainstem is close to regions
with an incomplete blood–brain barrier (Chaudhri et al., 2006; Yu
and Kim, 2012). This allows both the ARC and brainstem to receive
blood-borne signals, such as PYY. PYY3–36 induces anorexia through
binding to receptors Y2 on the presynaptic terminals of hypothalamic
NPY neurons so as to induce the inactivation of these neurons (Michel
et al., 1998).
PYY also affects the appetite via its effect on the ileal brake by in-
hibiting food intake once nutrients have reached the ileum (Lin et al.,
1996a, 1997; Lin et al., 1996b; Maljaars et al., 2007; Maljaars et al.,
2008a; Maljaars et al., 2008b; Ohtani et al., 2001; Pironi et al., 1993;
Van Citters and Lin, 1999, 2006).































































Fig. 2. The density of PYY cells in the ileum, colon and rectum of healthy
subjects and patients with IBS. ***,< 0.001. Data from (El-Salhy et al., 2014c;
El-Salhy et al., 2012a; El-Salhy and Gilja, 2017; El-Salhy et al., 2014a).
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4. Abnormalities in PYY in IBS
The density of PYY cells in the ileum does not differ between IBS
patients and healthy subjects (Fig. 2) (El-Salhy and Gilja, 2017; El-Salhy
et al., 2014a). However, the density of PYY cells and the concentration
of PYY, as detected by radioimmunoassay, in colon are both lower in
IBS patients than in healthy subjects (Figures and 3) (El-Salhy et al.,
2014c; El-Salhy et al., 2012a; Simren et al., 2003). Similar to the colon,
there are fewer PYY cells in the rectum of IBS patients than in healthy
subjects (Fig. 4) (El-Salhy et al., 2012b). However, postprandial level of
PYY did not differ from that of healthy subjects (Van Der Veek et al.,
2006) Fig. 3.
The cell densities of Musashi 1 and neurogenin 3 in the colon are
lower in IBS patients than in healthy subjects (El-Salhy et al., 2017; El-
Salhy and Gilja, 2017) (Fig. 5). Musashi 1 is a marker for intestinal stem
cells and their early progeny, while neurogenin 3 is a marker for early
intestinal endocrine cell progenitors (Fishbein et al., 2009; He et al.,
2007; Kayahara et al., 2003; Montgomery and Breault, 2008; Potten
et al., 2003; Schonhoff et al., 2004a, 2004b). In patients with congenital
malabsorptive diarrhoea and small-intestine allograft rejection, as well
as in NEUROG3-knockout mice, the reduction in neurogenin 3 seems to
result in a low density of enteroendocrine cells (Fishbein et al., 2009;
Jenny et al., 2002; Wang et al., 2006). Accordingly, it can be speculated
that changes in stem cells and enteroendocrine cells progenitors might
Fig. 3. PYY cells in the ileum, colon and rectum of healthy subjects (A, C and E) and patients with IBS (B, D and F). There were fewer PYY cells in the colon and
rectum of IBS patients than in the healthy subjects.
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be responsible for the low density of PYY cells in the large intestine (El-
Salhy et al., 2014d) (Fig. 6).
PYY cells express, as mentioned previously, also enteroglucagon
(oxyntomodulin) and GLP-1. The density of the large intestinal en-
teroglucagon cells are significantly reduced in patients with IBS (El-
Salhy et al., 2014c) (Fig. 4). Thus, the possibility that the reduction in
the number of PYY cells is caused by switching off the synthesis of PYY
and switching on the synthesis of enteroglucagon can be excluded (El-
Salhy et al., 2017). Whether PYY cells switch off the synthesis of PYY
and switch on the synthesis GLP-1 or other neuroendocrine peptides is
unclear (Habib et al., 2013).
5. PYY role in the pathophysiology of IBS
Based on the current knowledge of the physiological functions of PYY in
the gastrointestinal tract and the abnormalities seen in IBS, it can be
hypothesized that a low PYY concentration and a low density of PYY cells in
the large intestine would lead to a reduction in the amount of PYY released,
with this in turn contributing to the dysmotility seen in IBS. Furthermore,
since PYY modulates serotonin release, the low PYY concentration could
contribute to the visceral hypersensitivity observed in IBS patients.
6. Clinical implications
Diet management of IBS patients involving consuming a low-
FODMAP (fermentable oligo-, di-, and monosaccharides, and polyols)
diet was found to restore their PYY cell density to the normal level
(Mazzawi et al., 2015). This change was accompanied by an improve-
ment in abdominal symptoms (Mazzawi et al., 2013). The interaction
between dietary intake and the enteroendocrine cells is complicated
(El-Salhy and Gundersen, 2015; El-Salhy et al., 2019). These changes in
the density of PYY can be both cause and effect. The low density of PYY
cells could be caused by the unsuitable intake of dietary items by Pa-
tients with IBS and restoring the density of these cells could be an effect
of proper intake of food items (FODMAPs). The diet acts as a substrate
for intestinal microbiota (prebiotic) and food items ingested determine
the profile of the intestinal microbiota (El-Salhy et al., 2019). On the
other hand, intestinal bacteria ferments the undigested food in the in-
testinal lumen, which results in fermentation by-products including
short-chain fatty acids (SCFA) (El-Salhy et al., 2019). SCFA has been
found to increase the secretion and upregulate the gene expression of
PYY (Karaki et al., 2006; Samuel et al., 2008; Zhou et al., 2008). These
observations suggest that diet management would be the best approach
for correcting the PYY abnormalities seen in IBS patients in the clinic.
7. Conclusion
PYY plays an important role in regulating gastrointestinal motility,
secretion and absorption, as well in the appetite. IBS patients have a
low PYY concentration and also a low density of PYY cells in the large
intestine compared to healthy subjects. These abnormalities seem to
contribute to the dysmotility and visceral hypersensitivity seen in IBS
patients. A PYY receptor agonist without serious side-effects would be
ideal for IBS treatment. However, diet management appears to restore
the PYY cell density in the large intestine seems to be the most ap-
propriate approach to correct PYY abnormalities in the clinic.
Fig. 4. The densities of PYY and oxyntomodulin (enteroglucagon) in the ileum
and rectum of patients with IBS. There is no significant difference between the
denities of PYY and oxyntomodulin cells. As L-cells express both PYY and
oxyntomodulin, this shows that the low density of PYY cells is not caused by
down regulating the expression of PYY and upp-regulating the expression of
oxyntomodulin.
Fig. 5. Neurogenin 3 cells in the colon of a healthy subject (A) and in a patient with IBS (B). The density of neurogenin 3 is reduced in patients with IBS. The density
of neurogenin 3 cells is lower in IBS patients than healthy subjects. Data from (El-Sahy et al., 2017)-.
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